Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 9/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9044825 | 0.85 | SLC29A1 (0.69) | SLC29A1LMNARAB9ACYP3A4PKM | |
| SCHEMBL6630142 | 0.78 | ADORA2A (0.60) | SLC29A1ADORA3LMNA | |
| SCHEMBL8893178 | 0.77 | ADORA3 (0.66) | SLC29A1ADORA3LMNARAB9ACYP3A4 | |
| SCHEMBL6883248 | 0.75 | ADORA2A (0.54) | SLC29A1ADORA3 | |
| SCHEMBL6883241 | 0.75 | ADORA2A (0.54) | SLC29A1ADORA3 | |
| Phosphoric Acid SCHEMBL3291855 | 0.75 | ADORA2A (0.56) | SLC29A1ADORA3LMNA | |
| SCHEMBL3970946 | 0.74 | LMNA (0.62) | SLC29A1ADORA3LMNAHPGDSMN1; SMN2 | |
| SCHEMBL16555404 | 0.74 | LMNA (0.62) | SLC29A1ADORA3LMNAHPGDSMN1; SMN2 | |
| SCHEMBL5033515 | 0.74 | LMNA (0.62) | SLC29A1ADORA3LMNAHPGDSMN1; SMN2 | |
| SCHEMBL899617 | 0.74 | LMNA (0.62) | SLC29A1ADORA3LMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190282580-A1 | PRO-INFLAMMATORY ROLE FOR ADENOSINE UPTAKE AND METABOLISM | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY | 2019-09-19 | — | — | US | claimed |
| WO-2018089835-A1 | A PRO-INFLAMMATORY ROLE FOR ADENOSINE UPTAKE AND METABOLISM | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2018-05-17 | — | — | WO | claimed |
| US-20180008540-A1 | UNIT AEROSOL DOSES FOR ANTICOAGULATION | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-01-11 | — | — | US | claimed |
| EP-3247332-A1 | UNIT AEROSOL DOSES FOR ANTICOAGULATION | Incarda Therapeutics, Inc. (US) | 2017-11-29 | — | — | EP | claimed |
| WO-2016118625-A1 | UNIT AEROSOL DOSES FOR ANTICOAGULATION | INCARDA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | WO | claimed |
| EP-0814810-A4 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIV MASSACHUSETTS MEDICAL (US) | 1999-06-09 | — | — | EP | claimed |
| EP-0814810-A1 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1998-01-07 | — | — | EP | claimed |
| US-5629298-A | INCREASING CONTRACTILE PERFORMANCE, ADENOSINE TRANSPORT INHIBITORS USED AS POTENTIATORS | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1997-05-13 | — | — | US | claimed |
| WO-1996028163-A1 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1996-09-19 | — | — | WO | claimed |
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| CN-117440816-A | Modified MIR-135, conjugated forms thereof and uses thereof | 耶达研究及发展有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-11826366-B2 | Composition and methods for preventing or reducing the incidence of transient ischemic attacks | MOREHOUSE SCHOOL OF MEDICINE (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4277635-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | Yeda Research and Development Co. Ltd (IL) | 2023-11-22 | — | — | EP | disclosed |
| US-11547663-B2 | Unit aerosol doses for anticoagulation | INCARDA THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20040132981-A1 | Novel ligands and methods for preparing same | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2004-07-08 | — | — | US | disclosed |
| EP-1289561-A2 | LIGAND CONJUGATES AND METHODS FOR PREPARING SAME | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2003-03-12 | — | — | EP | disclosed |
| US-20010051348-A1 | Novel ligands and methods for preparing same | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2001-12-13 | — | — | US | disclosed |
| WO-2001054731-A2 | LIGAND CONJUGATES AND METHODS FOR PREPARING SAME | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2001-08-02 | — | — | WO | disclosed |
| WO-1989000854-A1 | METHODS FOR INCREASING EXTRACELLULAR ADENOSINE AND FOR STABILIZING MAST CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1989-02-09 | — | — | WO | disclosed |
| EP-0301900-A2 | L'utilisation de riboside ou ribotide de l'AICA pour la fabrication d'un médicament contre la crise cardiaque ou l'infarctus du myocarde aux patients souffrant d'athérosclerosis. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051348-A1 | Novel ligands and methods for preparing same | ADGRF1, ADGRE5, TACR2 | SLC29A1 1324/4885ADORA3 272/4885LMNA 3462/4885 |
| US-20040132981-A1 | Novel ligands and methods for preparing same | ADGRF1, ADGRE5, TACR2 | SLC29A1 1324/4885ADORA3 272/4885LMNA 3462/4885 |
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | METTL16, SYNCRIP, FBL | SLC29A1 2142/4885ADORA3 4707/4885LMNA 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.